Alvotech (ALVO) Cash from Financing Activities (2023 - 2026)
Alvotech's (ALVO) quarterly Cash from Financing Activities came in at $143.4 million in Q2 2026, up 72.44% on a YoY basis from $83.1 million in Q2 2025, and up 14926.89% quarter-over-quarter from -$967000.0 in Q1 2026.
Analysis
Alvotech (ALVO) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Alvotech (ALVO) has reported Cash from Financing Activities for 4 consecutive years, with $143.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities rose 72.44% year-over-year to $143.4 million; the trailing twelve-month figure through Jun 2026 stood at $335.9 million (up 41.49% YoY), and the FY2025 full-year result was $270.8 million, down 8.9% from the prior year.
- Cash from Financing Activities improved to $143.4 million in Q2 2026 per ALVO's latest filing, from -$967000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $206.8 million in Q4 2025 and bottomed at -$13.2 million in Q3 2025.
- Historically, Cash from Financing Activities has averaged $60.7 million across 4 years, with a median of $12.5 million in 2023.
- The widest YoY moves for Cash from Financing Activities: up 4713.06% in 2025, down 108.5% in 2025.
- Over 4 years, Cash from Financing Activities stood at $20.7 million in 2023, then tumbled by 79.21% to $4.3 million in 2024, then jumped by 4713.06% to $206.8 million in 2025, then slumped by 30.66% to $143.4 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $143.4 million, -$967000.0, and $206.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -1.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | -1.24 Bn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | -75.18 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | 79.36 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | -49.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 143.38 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | -4.65 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | -43.54 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 143.38 Mn |
| Mar 31, 2026 | -967,000.00 |
| Dec 31, 2025 | 206.77 Mn |
| Sep 30, 2025 | -13.25 Mn |
| Jun 30, 2025 | 83.15 Mn |
| Mar 31, 2025 | -5.84 Mn |
| Dec 31, 2024 | 4.30 Mn |
| Sep 30, 2024 | 155.83 Mn |
| Jun 30, 2024 | 4.00 Mn |
| Mar 31, 2024 | 133.18 Mn |
| Dec 31, 2023 | 20.66 Mn |
| Jun 30, 2023 | -2.73 Mn |